A random sample survey of 500 acute care hospitals in the United States was conducted to evaluate the adoption of extended-interval aminoglycoside dosing (EIAD). The survey revealed that EIAD has been adopted in 3 of every 4 acute care hospitals, a 4-fold increase since 1993. Of the 74.7% of hospitals reporting EIAD, 64% had written guidelines. Equal or less toxicity (87.1%), equal efficacy (76.9%), and cost-savings (65.6%) were common rationales. There has been a trend toward higher adult dosages of gentamicin (e.g., 15 mg/kg/dose) and an increase in the adoption of EIAD across all age groups (neonatal, 11%, and pediatric, 23%). Monitoring of aminoglycoside concentrations has shifted to a single determination of concentration, at 6-18 h after drug administration. The most common methods of dosage adjustment for declining renal function were an interval extension with the same dose (47%) or use of the Hartford nomogram (32%). Several meta-analyses addressing the efficacy and toxicity of EIAD have been published recently [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Overall, the metaanalyses concluded that EIAD was as effective as conventional dosing, with similar rates or a trend toward reduction of nephrotoxicity. With less frequent dosing, decreased preparation and administration costs, and reductions in monitoring of serum aminoglycoside concentrations, EIAD offers economic and practical advantages over conventional dosing [15] [16] [17] [18] [19] [20] [21] [22] . hospitals used EIAD. In addition, pharmacy residency programs and pharmacokinetic services appeared to be instrumental in EIAD implementation. Since 1993, additional literature on EIAD has been published, including information on dosing methods, efficacy and toxicity, and applications to other patient populations (e.g., pediatric, elderly, and immunocompromised patients) [3-15, 22, 24-31].
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There are several EIAD methods described in the literature [3, 4, 11, [24] [25] [26] [27] [28] [29] . The 2 initial EIAD methods originated from Hartford, Connecticut (the "Hartford nomogram") [3, 24] , and Portland, Oregon (the "Portland method") [25, 26] . These dosing methods differ in the dose per kilogram of weight, the means of initial-dosage adjustment for renal impairment, and the timing and interpretation of determinations of serum aminoglycoside concentrations. The literature has not resolved controversies regarding the optimal dose, adjustment method for declining renal function, and therapeutic-drug monitoring (i.e., role, timing, and frequency) [29, 32, 33] .
The purpose of this study was to determine how EIAD is being implemented across the nation. The objectives were to assess the adoption and perceptions of EIAD in 1998 and to compare these results with the 1993 survey findings.
Methods
Questionnaire and sample. The initial questionnaire was designed by our group in 1993 to investigate the use of EIAD. We made slight modifications to simplify and shorten the questionnaire, deleting questions regarding indications (i.e., prophylactic, empirical, or treatment) and administration (i.e., volume, infusion time, and method) and adding questions to elicit information on dose-modification and beliefs about nephrotoxicity. The remaining questions related to hospital demographics, clinical services, rationale for EIAD implementation, associated guidelines, contra- indications, monitoring, and potential cost-savings. The questionnaire consisted of check-off boxes and multiple-choice and short-answer questions to minimize completion time, to maximize response rates, and to facilitate data entry.
All acute care hospitals in the United States were eligible for inclusion. A simple random sample of 500 hospitals was selected from the 1997/1998 edition of the American Hospital Association Guide [34] . The questionnaire, with a self-addressed, stamped envelope, was mailed to each hospital in March 1998. It was directed to the attention of the director of pharmacy, but with the recommendation to seek the assistance of other pharmacists in the institution as necessary, to ensure that complete and accurate data were provided. To optimize the response rate, follow-up reminders (postcards) were mailed to nonresponders in April 1998. A preset cutoff date of 8 weeks from the initial mailing was utilized for responses.
Data analysis. Responses were entered into a personal computer-based relational database program (Access 97; Microsoft, Redmond, Washington). The data were analyzed in the same manner as the 1993 survey data, to allow for direct comparisons. By use of the US Bureau of the Census definitions [35] below, the respondents were grouped into 9 divisions based on geographic location, to allow for regional comparisons. The New England division includes Connecticut, Massachusetts, Maine, New Hampshire, Rhode Island, and Vermont; the middle Atlantic division, New Jersey, New York, and Pennsylvania; the south Atlantic division, the District of Columbia, Delaware, Florida, Georgia, Maryland, North and South Carolina, Virginia, and West Virginia; the east north central division, Illinois, Indiana, Michigan, Ohio, and Wisconsin; the east south central division, Alabama, Kentucky, Mississippi, and Tennessee; the west north central division, Iowa, Kansas, Minnesota, Missouri, and North and South Dakota; the west south central division, Arkansas, Louisiana, Oklahoma, and Texas; the mountain division, Arizona, Colorado, Idaho, Montana, New Mexico, Nevada, Utah, and Wyoming; and the Pacific division, Alaska, California, Hawaii, Oregon, and Washington.
Frequencies and descriptive statistics were used to characterize the population and survey responses. For x 2 analyses, licensed-bed sizes and occupied-bed sizes were grouped as !100, 100-199, 200-299, 300-399, and у400. For selected analyses, respondents were further categorized as large (у500-bed) or small (!500-bed) teaching hospitals or large (у200-bed) or small (!200-bed) nonteaching hospitals, on the basis of medical-school affiliation. These groupings are consistent with categories published by researchers at the Centers from Disease Control and Prevention [36] . The x 2 test was used to compare frequency distributions for contingencytable analyses.
was considered to be statistically significant. P ! .05
Results

Demographic characteristics.
A total of 249 questionnaires were returned by the preset cutoff date of 8 weeks after the initial mailing. The response rate was 49.8%. Responses were received from 48 states and the District of Columbia; none were received from Montana or Nevada. Summary data on hospital size, geographic region, ownership, and teaching affiliations are shown in tables 1 and 2. The respondents to this 1998 survey had demographic characteristics similar to the 1993 survey respondents, as shown by x 2 analysis. Licensed-bed sizes ranged from 15 to 1100 and occupied-bed sizes from 2 to 660. The majority of the hospitals were nonprofit (81.4%). The 171 nonprofit hospitals were characterized by respondents as self-owned (45%), as having a religious affiliation (28.1%), or as owned by the county (18.7%), other entity (16.4%), city (7.6%), federal government (4.5%), or state (2.3%).
Hospital affiliations with a medical, pharmacy, nursing, or allied-health teaching program were indicated by respondents (table 2) . On the basis of only medical-school affiliation, 57 Clinical services and EIAD. An analysis was performed to examine the use of EIAD and the existence of a pharmacy department-based pharmacokinetic service, infectious disease specialist/service, and whether a pharmacist participated in rounds in the infectious disease service. Pharmacokinetic service was defined as retrieval of data from patient medical records and oral or written follow-up with the prescriber. This service was provided by 210 (84.3%) of the responding hospitals, which represents a 22.1% increase since 1993. Pharmacokinetic services were provided in 168 (90.3%) of the hospitals that indicated they used EIAD. The provision of pharmacokinetic services was compared for the categories of bed size, geographic region, and ownership ( ) had an infectious n = 173 disease specialist/service available, and 28 (16.1%) of these hospitals indicated that a pharmacist participated in rounds with that service, taking an active role in the discussion and subsequent drug treatment of the patients. Compared with 1993, there was a 14.4% increase in availability of infectious disease specialist/service at the respondent hospitals, with only a 1.7% increase in pharmacist participation. Hospitals with any type of teaching affiliation were 10%-30% more likely to have an infectious disease specialist/service ( ). The majority P ! .05 (88%) of teaching hospitals had an infectious disease specialist/ service available. However, as with pharmacokinetic services, large nonteaching hospitals had an infectious disease specialist/ service more often than small nonteaching hospitals (88.1% vs. 52.8%, respectively; ) P ! .05 Information regarding the status of aminoglycosides on the hospital formulary was requested. Gentamicin continues to be the most common aminoglycoside found on hospital formularies, at 99.2%, followed by tobramycin and amikacin, at 86.7% and 62.7%, respectively. Netilmicin is used infrequently (0.8%). This order also reflects the aminoglycosides most commonly used in EIAD. Routine monitoring of aminoglycoside concentrations, defined as at least 1 determination of serum concentration for each patient receiving an iv aminoglycoside for 172 h, was performed by 234 (94%) of 249 respondents.
EIAD usage.
One hundred and eighty-six respondents (75%) indicated that iv aminoglycosides were administered as a total daily dose, given as a single infusion at a 24-h interval, or at a more prolonged interval for patients with decreased renal function. This represents a 4-fold increase since 1993 (19% vs. 75%). EIAD usage in the 9 regions ranged from 66% to 100%, up from 7.5%-30.8% in 1993, with an average increase of 57.3% (range, 44.2%-77.8%). Increases of 170% were noted in the New England and Mid-Atlantic regions. Four hospitals also used EIAD according to an institutional review board-approved research protocol. Summary data on hospital size, geographic region, ownership, and teaching affiliations for those hospitals using EIAD are shown in table 2. No significant differences were seen when bed size, region, or teaching affiliation was controlled for ( ). P 1 .05 EIAD was significantly more common in nonprofit than in ). P ! .05 The remaining results are based on the subset of 186 respondents that indicated EIAD was used at their hospital. Written guidelines for EIAD as routine patient care existed in 119 (64%) of the hospitals. This represents a 2.5-fold increase in the existence of guidelines since 1993 (25.4% in 1993 vs. 64% in 1998). Hospitals with written guidelines indicated approval by the pharmacy and therapeutics committee (61.3%), the pharmacy department (38.2%), infectious disease section (22.6%), and department of medicine (7%). The rationales most often provided for initiating EIAD were equal or less toxicity (87.1% of respondents), equal effectiveness (76.9%), and increased costsavings (65.6%). The belief that EIAD is innovative and progressive was indicated by 27.4% of hospitals as part of the rationale for instituting EIAD.
The survey also asked about whether the infectious disease specialist or the pharmacist was involved in initiating EIAD regimens for hospitalized patients. Thirty-nine hospitals (21%) did not have an infectious disease specialist/service. Pharmacists remain more often involved than infectious disease specialists in initiating EIAD. Among the responding hospitals, the infectious disease service was always involved at 10 (6.8%), sometimes involved at 101 (69.2%), and never involved at 35 (24%). The pharmacist was always involved at 71 hospitals (38.6%), sometimes involved at 101 (59.4%), and never involved at 12 (6.5%). No significant change was noted in the rate of pharmacists' involvement in sometimes or always initiating EIAD (84.2% in 1993; 90.5% in 1998). However, participation of the infectious disease specialist/service in sometimes or always initiating EIAD increased by almost 20% (57.1% in 1993; 76% in 1998). Table 4 lists the frequency of reported contraindications for 1998 and 1993. In general, the reported contraindications have risen since 1993. Enterococcal endocarditis and obesity were new additions to the 1998 survey. The ages of patients considered eligible for EIAD were reported. Twenty hospitals (10.7%) reported no age restrictions. EIAD was used for adults most frequently (99.5% of those aged 19-65 years and 71% of those aged у65 years). For pediatric patients, defined as those aged 1-18 years, EIAD was used by 23.1% of respondents. Unlike in 1993, when use of EIAD for neonates or infants aged !1 year was not reported, in 1998 21 hospitals (1.3%) reported such use.
The corresponding dosage ranges for adults and children are summarized in table 5 . There has been a shift toward higher adult dosage regimens for gentamicin and tobramycin. In 1993, the majority of respondents indicated use of gentamicin and tobramycin at a dosage of 3-5 mg/kg/dose (66.7% and 79.1%, respectively). In 1998, respondents reported using regimens of 3-5 mg/kg/dose and 15 mg/kg/dose equally often. The most common dosage range for amikacin remained 10-15 mg/kg/ dose (72.3%).
The monitoring of serum aminoglycoside concentrations for patients receiving EIAD was reported by 176 (94.6%) of the hospitals. One hundred and seventy-nine hospitals (96.2%) reported monitoring nephrotoxicity with serum creatinine measurements (table 6). Monitoring of serum aminoglycoside concentrations has shifted from primarily peak and trough determinations (70% in 1993) to determination of a single concentration at 6-18 h (61% in 1998). Measuring only troughs was reported by 30.7% of respondents. Frequency of monitoring concentrations was based on clinical judgement (63%) or an established interval of every third day of therapy (26%).
Patients with declining renal function during EIAD had their regimens adjusted by 1 of the following methods: extension of the dosing interval but use of the same mg/kg dose (46.8%); use of the Hartford nomogram [3, 24] (32.3%); a change to traditional dosing (27.4%); reduction in dose and extension of the interval (22%); or reduction in dose with use of the same interval (16.7%). Fifty percent of respondents, compared with 6.3% in 1993, indicated that clinical judgement is used in this situation; this option was not available on the 1993 survey. Fewer than 5% indicated that they used the Portland EIAD method [25] outlined in the Sanford Guide to Antimicrobial Therapy [26] to modify therapy.
There was an 18% increase (from 75.4% in 1993 to 93.5% in 1998) in the percentage of respondents that believed EIAD was more cost-effective. When asked whether EIAD reduces the risk of aminoglycoside-associated nephrotoxicity in comparison with traditional multiple-daily dosing, the majority of respondents were unsure (58.6%), whereas 27.4% agreed and 14% disagreed with the statement. As in 1993, very few respondents (6 [3.2%]) indicated that audiometric testing was performed to monitor for ototoxicity.
Discussion
The results of our survey demonstrate a 4-fold increase in the adoption of EIAD as routine patient care over the past 5 years. The reasons for such a dramatic expansion of EIAD include an increase in literature on EIAD methods, efficacy, and toxicity, and an expansion into various other patient populations [3-15, 22, 24-31] . In addition, 65.6% of respondents believed that EIAD provides cost savings.
Anaizi projected that the use rate of EIAD would increase to 80% by the year 2000 [37] . Our study, as well as an informal survey by the Infectious Diseases Society of America's Emerging Infections Network [38] , documents that the current rate of EIAD use in the United States is ∼70%-75%. Several other abstracts and preliminary reports also support our findings that the use of EIAD is growing at an impressive rate. Two studies in 1996 using an adapted version of our survey tool documented that EIAD was being used at a rate of 77% (103/134; 94% response rate) in Canada [39] and 57% (62/109; 33% response rate) in Illinois [40] . In contrast, a 1997 nationwide survey found an EIAD-utilization rate of only 47% (87/185; 38% response rate) [41] .
The disparity in EIAD-utilization rates may be explained by differences in definition of EIAD use, sampling methods, and nonresponse bias depending on response rates. Hsu et al. [41] point out that the Mid-Atlantic United States had a significantly lower adoption rate than the rest of the country, which is in direct contrast to our survey findings. Our survey revealed that the Mid-Atlantic region was found to have the greatest increase in EIAD use and had the second highest rate across the 9 regions we examined. Unfortunately, further comparison between studies is not possible since data from most of the other studies have been presented only in abstract form or in personal communications. The findings from our 2 surveys are the only published data documenting the momentum of EIAD use.
The Hartford EIAD method [3, 24] appears to be used increasingly. The current survey observed an upward shifting of gentamicin and tobramycin doses (i.e., 15 mg/kg/dose), extension of dosing intervals as a means of adjusting dosages for patients with decreased renal function (32%), and a single determination of serum concentration, at 6-18 h (61%). Although half of the respondents continue to use 3-5 mg/kg/dose, !5% use the Portland EIAD method [25, 26] to adjust for decreased renal function. In addition, only 6% of respondents indicated monitoring the serum aminoglycoside concentration for 18 hours as recommended by the Portland EIAD method. This may be a reflection of the most common EIAD method being reported in the literature. However, the variability in the dosages reported demonstrates the controversy that exists about the optimal dose in EIAD [29, 32, 33] .
The majority of hospitals determine the serum aminoglycoside concentration just once, at 6-18 h following administration. Although monitoring of peak and trough serum aminoglycoside concentrations has become less frequent, 31% of respondents reported measuring troughs only. This is a matter for concern since true trough concentrations are useful for monitoring drug accumulation but provide no data on the length of time the concentration has been below the MIC for the pathogen or the assay detection limit [32, 33] . We can only speculate that some of the respondents may not be monitoring "true troughs" but instead random serum aminoglycoside concentrations late in the dosing interval. At the other end of the spectrum are the 5% of hospitals that do not monitor serum aminoglycoside concentrations. Optimal therapeutic-drug monitoring remains controversial, but elimination of serum concentration monitoring is not supported or recommended by the EIAD literature [27-29, 32, 33] .
Our response rate of 49.8% ( ) was acceptable. Hown = 249 ever, this introduces nonresponse bias. Certain limitations exist with this mail survey: the data were self-reported, responses were not validated, and responses were sought from pharmacy directors, who may not be familiar with the EIAD concept or its use in their hospital. Therefore, it is unknown whether responses from infectious disease specialists would have differed.
The results of this survey are valid only for acute care hospitals and may not be generalizable to other settings. Even though the phrase "EIAD use in routine patient care" was used, the rates of EIAD use do not describe the actual extent of EIAD use in each hospital. Gin et al. found that only 34% of hospitals that had implemented EIAD used this type of aminoglycoside dosing у50% of the time [39] . More than 40% of institutions in their study stated that EIAD was infrequently used. Similarly, the informal survey by the Infectious Diseases Society of America's Emerging Infections Network [38] suggested that 55% of 2768 patients received treatment with EIAD. Although recent surveys indicate that EIAD is commonly implemented, its routine use in patient care may be limited to selected patients and specific settings. The pharmacy profession played an instrumental role in the early implementation of EIAD, as indicated by 1993 data. However, the 1998 survey did not reveal an association between EIAD and pharmacy residency programs; instead, EIAD use was related to the availability of an infectious disease specialist/ service (78.6% vs. 65.8%;
) and pharmacy-based phar-P ! .05 macokinetic service (80% vs. 46.2%;
). Pharmacists' in-P ! .05 volvement in sometimes or always initiating EIAD has remained high (190%), whereas involvement of an infectious disease specialist/service has increased by 20% since 1993 (to 76% in 1998). This may indicate that the more widespread implementation of EIAD has included the involvement of infectious disease physicians and pharmacists.
In conclusion, EIAD has been adopted in 3 of every 4 acute care hospitals in the United States, and infectious disease physicians and pharmacists are actively involved in implementing and monitoring EIAD. Compared with 1993, EIAD has increasingly been adopted for use across all age groups (although the majority of EIAD use continues to be among adults), and monitoring of peak and trough serum aminoglycoside concentrations has become less frequent. There has been an increase in the number of hospitals with written guidelines for EIAD, which corresponds to the 4-fold increase in the adoption of EIAD as routine patient care.
The rationale for initiating EIAD has been based on literature demonstrating equal efficacy, equal or less toxicity, and cost-savings compared to conventional dosing regimens [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Respondents indicated using clinical judgement more often for dosage adjustments and monitoring of EIAD, which may indicate increasing clinical experience and comfort with using EIAD. Although EIAD use has been increasingly adopted, clinicians must critically evaluate the literature and determine the type of aminoglycoside dosing that is appropriate for each patient and clinical setting [32] .
